What is Zoetis?
Zoetis is a animal health medicines, vaccines, and diagnostics company serving enterprise, public-sector, commercial, consumer, or regulated-market customers.
- Category
- Animal health medicines, vaccines, and diagnostics
- Headquarters
- Parsippany, NJ
- Founded
- See official company history
- Employees
- See latest annual report and company filings
- Total funding
- Public company
- Status
- Public company; NYSE: ZTS
What is Zoetis?
Zoetis is a animal health medicines, vaccines, and diagnostics company headquartered in Parsippany, NJ. Its public-company profile is most useful for account planning when combined with current filings, investor materials, job posts, product launches, and partner announcements.
Zoetis is a animal health medicines, vaccines, and diagnostics company headquartered in Parsippany, NJ. Its public-company profile is most useful for account planning when combined with current filings, investor materials, job posts, product launches, and partner announcements.
For sellers, Zoetis should be mapped as a scaled public-company account rather than an early-stage company. The best timing signals are earnings commentary, capital spending, hiring clusters, product launches, acquisitions, facility investments, and leadership changes.
What does Zoetis offer?
Zoetis's profile centers on Companion animal medicines, Livestock medicines, Vaccines, Diagnostics.
- Companion animal medicines· Animal health medicines, vaccines, and diagnostics
- Livestock medicines· Animal health medicines, vaccines, and diagnostics
- Vaccines· Animal health medicines, vaccines, and diagnostics
- Diagnostics· Animal health medicines, vaccines, and diagnostics
- Genetics· Animal health medicines, vaccines, and diagnostics
- Veterinary services· Animal health medicines, vaccines, and diagnostics
How does Zoetis make money?
Zoetis makes money through commercial activity tied to animal health medicines, vaccines, and diagnostics.
Zoetis monetizes through the model common to animal health medicines, vaccines, and diagnostics: product sales, recurring services, subscriptions, contracts, distribution, transaction volume, underwriting, regulated utility revenue, or usage depending on the operating unit.
Sales angles should connect to measurable priorities such as margin, growth, uptime, compliance, retention, automation, risk reduction, data quality, customer experience, or field productivity.
Who leads Zoetis?
Zoetis's named executives should be verified on the official leadership or investor-relations page before outreach.
- Zoetis executive leadershipExecutive leadership teamCurrent as of June 2026Use the official leadership, governance, or investor-relations page for current named executives before outreach.
- Zoetis finance leadershipFinance / CFO organizationCurrent as of June 2026Often owns investor communication, procurement governance, capital allocation, and budget discipline.
- Zoetis operations or technology leadershipOperations, product, technology, security, or commercial leadershipCurrent as of June 2026Likely stakeholder group for software, infrastructure, data, workflow, and operating-improvement purchases.
How do you contact Zoetis's leadership?
Zoetis should be contacted through official investor, media, partner, support, or sales routes unless a named executive publishes a direct address.
contact via https://www.zoetis.comHow is Zoetis funded?
Zoetis's current status is Public company; NYSE: ZTS.
Zoetis's capital profile is best understood through its current public-company status: Public company; NYSE: ZTS. For public companies, financing and budget signals are usually found in annual reports, quarterly results, debt disclosures, buybacks, acquisitions, capex plans, and management commentary rather than venture funding rounds.
Before outreach, verify the latest status on the company's investor-relations page and current exchange filings.
How did Zoetis get here?
Zoetis's history should be read through founding, scale-up, public-market ownership, and current product or market focus.
- FoundingZoetis is foundedThe company begins building in animal health medicines, vaccines, and diagnostics.
- Scale-upCommercial footprint expandsZoetis broadens its product, customer, distribution, or geographic reach.
- Public marketsPublic company; NYSE: ZTSPublic-company ownership shapes reporting, procurement, and operating priorities.
- 2025Scaled operating profileThe company operates with specialized teams and repeatable buying centers.
- June 2026Current profile refreshedProfile generated from official domain, public-company status, and source references.
Who are Zoetis's competitors?
Zoetis competes with larger incumbents and focused specialists in animal health medicines, vaccines, and diagnostics.
- Thermo Fisher ScientificLife sciences tools, diagnostics, and services incumbent.
- DanaherLife sciences and diagnostics platform company.
- MedtronicGlobal medical technology competitor.
- PfizerLarge pharmaceutical company with global commercial reach.
- IQVIAHealthcare data and clinical research platform competitor.
Zoetis — frequently asked questions
